ACTUATE THERAPEUTICS, INC.(ACTU)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ACTU Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ACTUATE THERAPEUTICS, INC. (ACTU), a Healthcare sector company. ACTU is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), ACTUATE THERAPEUTICS, INC. reports net income of $-5.6M, free cash flow of $-5.0M. Top institutional holders of ACTU by reported 13-F value include BIOS Capital Management,, Voss Capital,, BlackRock,, based on the most recent SEC filings. ACTU trades on the Nasdaq exchange and files with the SEC under CIK 1652935. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACTU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ACTUATE THERAPEUTICS, INC. directly from SEC EDGAR.
Net Income
Q1 2026
$-5.6M
Free Cash Flow
Q1 2026
$-5.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+10.2% YoYOperating Income
+9.9% YoYEPS (Diluted)
+93.9% YoYTotal Assets
+368.6% YoYOp. Cash Flow
+11.2% YoY| Metric | FY 2025 | FY 2023 | FY 2022 |
|---|---|---|---|
| Net Income | $-22.2M +10.2% | $-24.7M | — |
| Operating Income | $-22.5M +9.9% | $-25.0M | — |
| EPS (Diluted) | $-1.06 +93.9% | $-17.24 | — |
| Total Assets | $14.0M +368.6% | $3.0M | — |
| Operating Cash Flow | $-19.2M +11.2% | $-21.6M | — |
AI Insight: ACTU Financial Trends
Pre-revenue biotech burning $5–6M quarterly with equity swinging from negative to positive, suggesting recent financing but no clear path to profitability.
• Net income and operating income stable around $5–6M losses per quarter; operating cash burn narrowed to $4–5M in Q2 2025 and Q4 2025.
• Equity recovered from $114M deficit in Q2 2024 to $4M positive in Q1 2026, indicating capital raise or debt conversion.
⚠ No revenue reported across all eight quarters; cash burn remains material despite equity improvement.
⚠ Operating cash flow volatile (−$4M to −$9M), with no sign of clinical/commercial inflection.
AI Insight: ACTU Ratio Trends
Insufficient data: only one profitability metric (Q3 2025 ROE of -197.8%) available across nine periods; comprehensive trend analysis not possible.
• Q3 2025 ROE of -197.8% indicates significant net loss in that quarter; no other profitability or efficiency metrics reported.
⚠ Complete absence of OpMargin, NPM, ROA, ROIC, and D/E data across all periods prevents assessment of operational health or leverage trends.
Get alerted when ACTU's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ACTUATE THERAPEUTICS, INC. including:
Top Institutional Holders of ACTU
BIOS Capital Management, LP
$27.5M10,049,996 shVoss Capital, LP
$4.7M1,725,000 shBlackRock, Inc.
$1.2M427,153 shVANGUARD CAPITAL MANAGEMENT LLC
$1.1M400,529 shGEODE CAPITAL MANAGEMENT, LLC
$625.6K228,331 shConnective Capital Management, LLC
$310.3K113,266 shPalogic Value Management, L.P.
$274.0K100,000 shNORTHERN TRUST CORP
$268.1K97,851 shTexas Capital Bank Wealth Management Services Inc
$259.2K94,592 shSTATE STREET CORP
$180.9K66,030 sh
| Fund | Value | Shares |
|---|---|---|
| BIOS Capital Management, LP | $27.5M | 10,049,996 |
| Voss Capital, LP | $4.7M | 1,725,000 |
| BlackRock, Inc. | $1.2M | 427,153 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.1M | 400,529 |
| GEODE CAPITAL MANAGEMENT, LLC | $625.6K | 228,331 |
| Connective Capital Management, LLC | $310.3K | 113,266 |
| Palogic Value Management, L.P. | $274.0K | 100,000 |
| NORTHERN TRUST CORP | $268.1K | 97,851 |
| Texas Capital Bank Wealth Management Services Inc | $259.2K | 94,592 |
| STATE STREET CORP | $180.9K | 66,030 |
More Healthcare Companies
View all Healthcare →Put ACTU on your watchlist
Track score changes the day ACTUATE THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ACTU a good stock to buy?
13F Pro's AI-powered analysis of ACTUATE THERAPEUTICS, INC. (ACTU) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ACTU are available on the ACTU stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ACTU?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ACTU. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ACTUATE THERAPEUTICS, INC.'s investment landscape.